These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Mandel S; Weinreb O; Amit T; Youdim MB Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677 [TBL] [Abstract][Full Text] [Related]
27. Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review. Silver DE; Buck PO Int J Neurosci; 2011 Sep; 121(9):485-9. PubMed ID: 21671840 [TBL] [Abstract][Full Text] [Related]
28. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Parkinson Study Group Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852 [TBL] [Abstract][Full Text] [Related]
30. Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease. Solís-García del Pozo J; Mínguez-Mínguez S; de Groot PW; Jordán J Expert Opin Drug Saf; 2013 Jul; 12(4):479-86. PubMed ID: 23634791 [TBL] [Abstract][Full Text] [Related]
31. The use of rasagiline in Parkinson's disease. Schapira AH J Neural Transm Suppl; 2006; (71):157-61. PubMed ID: 17447426 [TBL] [Abstract][Full Text] [Related]
32. Determination of minimal clinically important change in early and advanced Parkinson's disease. Hauser RA; Auinger P; Mov Disord; 2011 Apr; 26(5):813-8. PubMed ID: 21437987 [TBL] [Abstract][Full Text] [Related]
33. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. Jost WH; Klasser M; Reichmann H Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504 [TBL] [Abstract][Full Text] [Related]
35. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. Stocchi F; Rabey JM Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884 [TBL] [Abstract][Full Text] [Related]
36. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. Bar-Am O; Weinreb O; Amit T; Youdim MB J Neurochem; 2010 Mar; 112(5):1131-7. PubMed ID: 20002521 [TBL] [Abstract][Full Text] [Related]
37. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Parkinson Study Group Arch Neurol; 2002 Dec; 59(12):1937-43. PubMed ID: 12470183 [TBL] [Abstract][Full Text] [Related]
38. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Guay DR Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539 [TBL] [Abstract][Full Text] [Related]
39. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Wesnes KA; McKeith I; Edgar C; Emre M; Lane R Neurology; 2005 Nov; 65(10):1654-6. PubMed ID: 16301500 [TBL] [Abstract][Full Text] [Related]
40. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E; Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]